Answer
Breastfeeding should be discontinued during treatment with Vargatef (nintedanib), because a risk to the breastfed child cannot be excluded and excretion of nintedanib and its metabolites into human milk is unknown.
Sources for this answer
- Vargatef 100 mg and 150 mg soft capsulesBoehringer Ingelheim Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 24Document updated
Sources checked